Imugene Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMU.AX research report →
Price Chart
About the company
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer.
- CEO
- Leslie Chong
- IPO
- 1993
- Employees
- 15
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on IMU.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $40.16M
- P/E
- -0.37
- Fwd P/E
- 0.05
- PEG
- -0.00
- P/S
- 12.80
- P/B
- 0.57
- EV/EBITDA
- -0.53
- Div Yield
- 0.00%
- Gross Margin
- -65.91%
- Op Margin
- -1960.77%
- Net Margin
- -1864.12%
- ROE
- -134.65%
- ROIC
- -108.88%
Latest fiscal year · YoY change
- Revenue
- $4.40M-11.5%
- Gross Profit
- $4.40M-11.5%
- Op Income
- $-70,940,449
- Net Income
- $-69,021,612+53.9%
- EPS
- $-0.32+55.6%
- OCF Growth
- +25.7%
- FCF Growth
- +17.3%
- 52W High
- $0.46
- 52W Low
- $0.08
- 50D MA
- $0.10
- 200D MA
- $0.19
- Beta
- 2.09
- RSI (14)
- 38
- Avg Volume
- 3.29M
No earnings-call transcripts are available for IMU.AX yet.
- Free Float
- 66.8%
- Shares Outstanding
- 489.72M
- Float Shares
- 327.33M
of shares held by institutions
1 13F filers
Our IMU.AX coverage
Recent articles, reports, and earnings notes.
No research on IMU.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMU.AX report →Figma shares rise as Bank of America resumes coverage with a ‘Buy’ rating
proactiveinvestors.com · Jul 7
Imugene raises $11.1 million to advance azer-cel after complete responses in early cohort
proactiveinvestors.com · Jul 7
Shell flags 'significantly higher' gas trading and sells South Africa business - UPDATE
proactiveinvestors.com · Jul 7
Imugene reports second BTKi cohort response - ICYMI
proactiveinvestors.com · Jul 4
Imugene CEO details azer-cel trial milestone - ICYMI
proactiveinvestors.com · Jul 3
Anthropic clears export hurdle for Fable 5, easing a threat to its IPO story
proactiveinvestors.com · Jul 1
Imugene reports second complete response in azer-cel BTKi cohort
proactiveinvestors.com · Jul 1
Fed may adopt leaner communications strategy under Warsh, says Deutsche Bank
proactiveinvestors.com · Jul 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.